Stephen V Frye

List of Publications by Year
in descending order

137 papers	11,864 citations	36303 51 h-index	28297 105 g-index
146 all docs	146 docs citations	146 times ranked	17252 citing authors

#	Article	IF	Citations
1	Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of Î±-Ketoglutarate-Dependent Dioxygenases. Cancer Cell, 2011, 19, 17-30.	16.8	2,340
2	The promise and peril of chemical probes. Nature Chemical Biology, 2015, 11, 536-541.	8.0	698
3	Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. Cell, 2012, 149, 307-321.	28.9	637
4	A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells. Nature Chemical Biology, 2011, 7, 566-574.	8.0	465
5	An Orally Bioavailable Chemical Probe of the Lysine Methyltransferases EZH2 and EZH1. ACS Chemical Biology, 2013, 8, 1324-1334.	3.4	399
6	The art of the chemical probe. Nature Chemical Biology, 2010, 6, 159-161.	8.0	357
7	Too many roads not taken. Nature, 2011, 470, 163-165.	27.8	341
8	Discovery of Î²-Arrestinâ€"Biased Dopamine D ₂ Ligands for Probing Signal Transduction Pathways Essential for Antipsychotic Efficacy. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 18488-18493.	7.1	312
9	Oxindole-Based Inhibitors of Cyclin-Dependent Kinase 2 (CDK2):Â Design, Synthesis, Enzymatic Activities, and X-ray Crystallographic Analysis. Journal of Medicinal Chemistry, 2001, 44, 4339-4358.	6.4	259
10	Discovery of an in Vivo Chemical Probe of the Lysine Methyltransferases G9a and GLP. Journal of Medicinal Chemistry, 2013, 56, 8931-8942.	6.4	220
11	Discovery of a 2,4-Diamino-7-aminoalkoxyquinazoline as a Potent and Selective Inhibitor of Histone Lysine Methyltransferase G9a. Journal of Medicinal Chemistry, 2009, 52, 7950-7953.	6.4	206
12	The discovery of potent cRaf1 kinase inhibitors. Bioorganic and Medicinal Chemistry Letters, 2000, 10, 223-226.	2.2	204
13	Structure and Inhibition of Microbiome Î²-Glucuronidases Essential to the Alleviation of Cancer Drug Toxicity. Chemistry and Biology, 2015, 22, 1238-1249.	6.0	203
14	Selective inhibition of EZH2 and EZH1 enzymatic activity by a small molecule suppresses MLL-rearranged leukemia. Blood, 2015, 125, 346-357.	1.4	188
15	Protein Lysine Methyltransferase G9a Inhibitors: Design, Synthesis, and Structure Activity Relationships of 2,4-Diamino-7-aminoalkoxy-quinazolines.. Journal of Medicinal Chemistry, 2010, 53, 5844-5857.	6.4	177
16	Chelates as intermediates in nucleophilic additions to alkoxy ketones according to Cram's rule (cyclic) Tj ETQq0 0 0 rgBT /Overlock 10 T	13.7	161
17	Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors. Science, 2001, 291, 134-137.	12.6	160
18	Discovery of a chemical probe for the L3MBTL3 methyllysine reader domain. Nature Chemical Biology, 2013, 9, 184-191.	8.0	160

#	Article	IF	Citations
19	A cellular chemical probe targeting the chromodomains of Polycomb repressive complex 1. Nature Chemical Biology, 2016, 12, 180-187.	8.0	133
20	Optimization of Cellular Activity of G9a Inhibitors 7-Aminoalkoxy-quinazolines. Journal of Medicinal Chemistry, 2011, 54, 6139-6150.	6.4	127
21	UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor. Journal of Medicinal Chemistry, 2014, 57, 7031-7041.	6.4	125
22	MERTK receptor tyrosine kinase is a therapeutic target in melanoma. Journal of Clinical Investigation, 2013, 123, 2257-2267.	8.2	124
23	Structureâ€"Functional Selectivity Relationship Studies of Î²-Arrestin-Biased Dopamine D₂ Receptor Agonists. Journal of Medicinal Chemistry, 2012, 55, 7141-7153.	6.4	118
24	Small-Molecule Ligands of Methyl-Lysine Binding Proteins. Journal of Medicinal Chemistry, 2011, 54, 2504-2511.	6.4	115
25	AMP Is an Adenosine A1 Receptor Agonist. Journal of Biological Chemistry, 2012, 287, 5301-5309.	3.4	113
26	US academic drug discovery. Nature Reviews Drug Discovery, 2011, 10, 409-410.	46.4	96
27	Are chelates truly intermediates in Cram's chelate rule?. Journal of the American Chemical Society, 1990, 112, 6130-6131.	13.7	89
28	Structure-activity relationship homology (SARAH): a conceptual framework for drug discovery in the genomic era. Chemistry and Biology, 1999, 6, R3-R7.	6.0	89
29	Screening for Inhibitors of Low-Affinity Epigenetic Peptide-Protein Interactions: An AlphaScreenâ„¢-Based Assay for Antagonists of Methyl-Lysine Binding Proteins. Journal of Biomolecular Screening, 2010, 15, 62-71.	2.6	88
30	TAM Family Receptor Kinase Inhibition Reverses MDSC-Mediated Suppression and Augments Antiâ€"PD-1 Therapy in Melanoma. Cancer Immunology Research, 2019, 7, 1672-1686.	3.4	85
31	Discovery of a Selective, Substrate-Competitive Inhibitor of the Lysine Methyltransferase SETD8. Journal of Medicinal Chemistry, 2014, 57, 6822-6833.	6.4	81
32	Donated chemical probes for open science. ELife, 2018, 7, .	6.0	80
33	Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia. ACS Medicinal Chemistry Letters, 2012, 3, 129-134.	2.8	67
34	6-Azasteroids: Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase. Journal of Medicinal Chemistry, 1994, 37, 2352-2360.	6.4	66
35	Small-Molecule Ligands of Methyl-Lysine Binding Proteins: Optimization of Selectivity for L3MBTL3. Journal of Medicinal Chemistry, 2013, 56, 7358-7371.	6.4	66
36	Rapid-injection nuclear magnetic resonance investigation of the reactivity of .alpha.- and .beta.-alkoxy ketones with dimethylmagnesium: kinetic evidence for chelation. Journal of the American Chemical Society, 1987, 109, 1862-1863.	13.7	65

#	Article	IF	Citations
37	Exploiting an Allosteric Binding Site of PRMT3 Yields Potent and Selective Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 2110-2124.	6.4	64
38	The Lipid Kinase PIP5K1C Regulates Pain Signaling and Sensitization. Neuron, 2014, 82, 836-847.	8.1	64
39	Tackling reproducibility in academic preclinical drug discovery. Nature Reviews Drug Discovery, 2015, 14, 733-734.	46.4	62
40	MerTK as a therapeutic target in glioblastoma. Neuro-Oncology, 2018, 20, 92-102.	1.2	62
41	Discovery and Clinical Development of Dutasteride, a Potent Dual 5α- Reductase Inhibitor. Current Topics in Medicinal Chemistry, 2006, 6, 405-421.	2.1	60
42	Application of Multiplexed Kinase Inhibitor Beads to Study Kinome Adaptations in Drug-Resistant Leukemia. PLoS ONE, 2013, 8, e66755.	2.5	60
43	Assessing the Cell Permeability of Bivalent Chemical Degraders Using the Chloroalkane Penetration Assay. ACS Chemical Biology, 2020, 15, 290-295.	3.4	60
44	Tumor Endothelial Cells with Distinct Patterns of TGFÎ²-Driven Endothelial-to-Mesenchymal Transition. Cancer Research, 2015, 75, 1244-1254.	0.9	59
45	UNC1062, a new and potent Mer inhibitor. European Journal of Medicinal Chemistry, 2013, 65, 83-93.	5.5	58
46	UNC2025, a MERTK Small-Molecule Inhibitor, Is Therapeutically Effective Alone and in Combination with Methotrexate in Leukemia Models. Clinical Cancer Research, 2017, 23, 1481-1492.	7.0	58
47	6-Azasteroids: potent dual inhibitors of human type 1 and 2 steroid 5.alpha.-reductase. Journal of Medicinal Chemistry, 1993, 36, 4313-4315.	6.4	56
48	Bringing together the academic drug discovery community. Nature Reviews Drug Discovery, 2013, 12, 811-812.	46.4	56
49	Identification of a Fragment-like Small Molecule Ligand for the Methyl-lysine Binding Protein, 53BP1. ACS Chemical Biology, 2015, 10, 1072-1081.	3.4	56
50	The MERTK/FLT3 inhibitor MRX-2843 overcomes resistance-conferring FLT3 mutations in acute myeloid leukemia. JCI Insight, 2016, 1, e85630.	5.0	55
51	Structure-Activity Relationships for Inhibition of Type 1 and 2 Human 5.alpha.-Reductase and Human Adrenal 3.beta.-Hydroxy-.DELTA.5-steroid Dehydrogenase/3-Keto-.DELTA.5-steroid Isomerase by 6-Azaandrost-4-en-3-ones: Optimization of the C17 Substituent. Journal of Medicinal Chemistry, 1995, 38, 2621-2627.	6.4	54
52	Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 9683-9692.	6.4	54
53	Canonical PRC1 controls sequence-independent propagation of Polycomb-mediated gene silencing. Nature Communications, 2019, 10, 1931.	12.8	54
54	Asymmetric synthesis based on 1,3-oxathianes. 4. Mechanism of asymmetric induction in the reactions of oxathianyl ketones. Journal of the American Chemical Society, 1988, 110, 484-489.	13.7	53

#	Article	IF	Citations
55	UNC569, a Novel Small-Molecule Mer Inhibitor with Efficacy against Acute Lymphoblastic Leukemia <i>In Vitro</i> and <i>In Vivo</i>. Molecular Cancer Therapeutics, 2013, 12, 2367-2377.	4.1	53
56	Aymmetric synthesis of () - and ()-citramalate in high enantiomeric purity. Tetrahedron Letters, 1985, 26, 3907-3910.	1.4	52
57	Identification of Non-Peptide Malignant Brain Tumor (MBT) Repeat Antagonists by Virtual Screening of Commercially Available Compounds. Journal of Medicinal Chemistry, 2010, 53, 7625-7631.	6.4	52
58	MERTK inhibition alters the PD-1 axis and promotes anti-leukemia immunity. JCI Insight, 2018, 3, .	5.0	51
59	Chromodomain Ligand Optimization via Target-Class Directed Combinatorial Repurposing. ACS Chemical Biology, 2016, 11, 2475-2483.	3.4	46
60	Application of a MYC degradation screen identifies sensitivity to CDK9 inhibitors in KRAS-mutant pancreatic cancer. Science Signaling, 2019, 12, .	3.6	46
61	Small Molecule Inhibition of MERTK Is Efficacious in Nonâ€“Small Cell Lung Cancer Models Independent of Driver Oncogene Status. Molecular Cancer Therapeutics, 2015, 14, 2014-2022.	4.1	45
62	Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis. Journal of Medicinal Chemistry, 2013, 56, 9693-9700.	6.4	43
63	Discovery of Peptidomimetic Ligands of EED as Allosteric Inhibitors of PRC2. ACS Combinatorial Science, 2017, 19, 161-172.	3.8	43
64	Accessing Protein Methyltransferase and Demethylase Enzymology Using Microfluidic Capillary Electrophoresis. Chemistry and Biology, 2010, 17, 695-704.	6.0	41
65	Target 2035 â€“ update on the quest for a probe for every protein. RSC Medicinal Chemistry, 2022, 13, 13-21.	3.9	39
66	Discovery and Characterization of a Cellular Potent Positive Allosteric Modulator of the Polycomb Repressive Complex 1 Chromodomain, CBX7. Cell Chemical Biology, 2019, 26, 1365-1379.e22.	5.2	38
67	Inhibition of Inositol Polyphosphate Kinases by Quercetin and Related Flavonoids: A Structureâ€“Activity Analysis. Journal of Medicinal Chemistry, 2019, 62, 1443-1454.	6.4	38
68	Efficacy of a Mer and Flt3 tyrosine kinase small molecule inhibitor, UNC1666, in acute myeloid leukemia. Oncotarget, 2015, 6, 6722-6736.	1.8	38
69	Prevention of chelation by an oxygen function through protection with a triisopropyl silyl group. Tetrahedron Letters, 1986, 27, 3223-3226.	1.4	37
70	Synthesis of 2-aminobenzophenones via rapid halogen-lithium exchange in the presence of a 2-amino-N-methoxy-N-methylbenzamide. Journal of Organic Chemistry, 1991, 56, 3750-3752.	3.2	37
71	MERTK Mediates Intrinsic and Adaptive Resistance to AXL-targeting Agents. Molecular Cancer Therapeutics, 2018, 17, 2297-2308.	4.1	36
72	Non-enzymatic asymmetric synthesis of (R)-(-)- and (S)-(+)-mevalolactone in high enantiomeric purity. Journal of Organic Chemistry, 1985, 50, 3402-3404.	3.2	35

#	Article	IF	Citations
73	Biophysical Probes Reveal a â€œCompromiseâ€• Nature of the Methyl-lysine Binding Pocket in L3MBTL1. Journal of the American Chemical Society, 2011, 133, 5357-5362.	13.7	35
74	Structureâ€"activity relationships of methyl-lysine reader antagonists. MedChemComm, 2012, 3, 45-51.	3.4	33
75	Chromatin remodeling controls Kaposi's sarcoma-associated herpesvirus reactivation from latency. PLoS Pathogens, 2018, 14, e1007267.	4.7	32
76	Target class drug discovery. Nature Chemical Biology, 2017, 13, 1053-1056.	8.0	31
77	Drug Discovery Toward Antagonists of Methyl-Lysine Binding Proteins. Current Chemical Genomics, 2011, 5, 51-61.	2.0	31
78	Writing and Rewriting the Epigenetic Code of Cancer Cells: From Engineered Proteins to Small Molecules. Molecular Pharmacology, 2013, 83, 563-576.	2.3	30
79	Targeting Chromatin Readers. Clinical Pharmacology and Therapeutics, 2013, 93, 312-314.	4.7	29
80	Epigenetics: tools and technologies. Drug Discovery Today: Technologies, 2010, 7, e59-e65.	4.0	28
81	Structureâ€"Activity Relationships and Kinetic Studies of Peptidic Antagonists of CBX Chromodomains. Journal of Medicinal Chemistry, 2016, 59, 8913-8923.	6.4	28
82	High-throughput small molecule screen identifies inhibitors of aberrant chromatin accessibility. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 3018-3023.	7.1	26
83	Orally Active Adenosine A1 Receptor Agonists with Antinociceptive Effects in Mice. Journal of Medicinal Chemistry, 2012, 55, 6467-6477.	6.4	25
84	Discovery of Macrocyclic Pyrimidines as MerTKâ€Specific Inhibitors. ChemMedChem, 2017, 12, 207-213.	3.2	25
85	MERTK Promotes Resistance to Irreversible EGFR Tyrosine Kinase Inhibitors in Nonâ€"small Cell Lung Cancers Expressing Wild-type <i>EGFR</i> Family Members. Clinical Cancer Research, 2018, 24, 6523-6535.	7.0	25
86	A General TR-FRET Assay Platform for High-Throughput Screening and Characterizing Inhibitors of Methyl-Lysine Reader Proteins. SLAS Discovery, 2019, 24, 693-700.	2.7	25
87	The structureâ€"activity relationships of L3MBTL3 inhibitors: flexibility of the dimer interface. MedChemComm, 2013, 4, 1501.	3.4	24
88	Chemical probes for methyl lysine reader domains. Current Opinion in Chemical Biology, 2016, 33, 135-141.	6.1	24
89	Inhibition of MERTK Promotes Suppression of Tumor Growth in BRAF Mutant and BRAF Wild-Type Melanoma. Molecular Cancer Therapeutics, 2019, 18, 278-288.	4.1	24
90	MERTK Inhibition Induces Polyploidy and Promotes Cell Death and Cellular Senescence in Glioblastoma Multiforme. PLoS ONE, 2016, 11, e0165107.	2.5	23

#	Article	IF	Citations
91	Highly Selective MERTK Inhibitors Achieved by a Single Methyl Group. Journal of Medicinal Chemistry, 2018, 61, 10242-10254.	6.4	20
92	Design and Synthesis of Novel Macrocyclic Mer Tyrosine Kinase Inhibitors. ACS Medicinal Chemistry Letters, 2016, 7, 1044-1049.	2.8	19
93	UNC569 As Novel Small Molecule Mer Receptor Tyrosine Kinase Inhibitor for Treatment of ALL. Blood, 2011, 118, 2589-2589.	1.4	17
94	Quantitative Characterization of Bivalent Probes for a Dual Bromodomain Protein, Transcription Initiation Factor TFIID Subunit 1. Biochemistry, 2018, 57, 2140-2149.	2.5	16
95	Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 16541-16550.	7.1	16
96	MerTK inhibition decreases immune suppressive glioblastoma-associated macrophages and neoangiogenesis in glioblastoma microenvironment. Neuro-Oncology Advances, 2020, 2, vdaa065.	0.7	16
97	Use of Protein Kinaseâ€“Focused Compound Libraries for the Discovery of New Inositol Phosphate Kinase Inhibitors. SLAS Discovery, 2018, 23, 982-988.	2.7	15
98	Improved methods for targeting epigenetic reader domains of acetylated and methylated lysine. Current Opinion in Chemical Biology, 2021, 63, 132-144.	6.1	14
99	Inhibitors paradoxically prime kinases. Nature Chemical Biology, 2009, 5, 448-449.	8.0	12
100	Data-Driven Construction of Antitumor Agents with Controlled Polypharmacology. Journal of the American Chemical Society, 2019, 141, 15700-15709.	13.7	12
101	Discovery of selective activators of PRC2 mutant EED-I363M. Scientific Reports, 2019, 9, 6524.	3.3	12
102	Design and Construction of a Focused DNA-Encoded Library for Multivalent Chromatin Reader Proteins. Molecules, 2020, 25, 979.	3.8	12
103	Discovery and Optimization of 2<i>H</i>-1Î»²-Pyridin-2-one Inhibitors of Mutant Isocitrate Dehydrogenase 1 for the Treatment of Cancer. Journal of Medicinal Chemistry, 2021, 64, 4913-4946.	6.4	12
104	Discovery of an H3K36me3-Derived Peptidomimetic Ligand with Enhanced Affinity for Plant Homeodomain Finger Protein 1 (PHF1). Journal of Medicinal Chemistry, 2021, 64, 8510-8522.	6.4	12
105	Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chemical Biology, 2022, 29, 555-571.e11.	5.2	12
106	MERTK activation drives osimertinib resistance in EGFR-mutant nonâ€“small cell lung cancer. Journal of Clinical Investigation, 2022, 132, .	8.2	12
107	Discovery and Characterization of Peptide Inhibitors for Calcium and Integrin Binding Protein 1. ACS Chemical Biology, 2020, 15, 1505-1516.	3.4	11
108	The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells. Epigenetics and Chromatin, 2020, 13, 44.	3.9	10

#	Article	IF	Citations
109	Publication Criteria and Requirements for Studies on Protein Kinase Inhibitorsâ"€What Is Expected?. Journal of Medicinal Chemistry, 2022, 65, 6973-6974.	6.4	10
110	Targeting Methyl Lysine. Annual Reports in Medicinal Chemistry, 2010, 45, 329-343.	0.9	9
111	Design, synthesis, and protein methyltransferase activity of a unique set of constrained amine containing compounds. Bioorganic and Medicinal Chemistry Letters, 2016, 26, 4436-4440.	2.2	8
112	The L3MBTL3 Methyl-Lysine Reader Domain Functions As a Dimer. ACS Chemical Biology, 2016, 11, 722-728.	3.4	8
113	Development of [18F]MIPS15692, a radiotracer with inÂvitro proof-of-concept for the imaging of MER tyrosine kinase (MERTK) in neuroinflammatory disease. European Journal of Medicinal Chemistry, 2021, 226, 113822.	5.5	5
114	Unlocking the potential of chemical probes for methyl-lysine reader proteins. Future Medicinal Chemistry, 2015, 7, 1831-1833.	2.3	4
115	Peptide Technologies in the Development of Chemical Tools for Chromatinâ€Associated Machinery. Drug Development Research, 2017, 78, 300-312.	2.9	4
116	UNC5293, a potent, orally available and highly MERTK-selective inhibitor. European Journal of Medicinal Chemistry, 2021, 220, 113534.	5.5	4
117	Bone Marrow Stromal Cell Mediated Resistance to Mertk Inhibition in Acute Leukemia. Blood, 2016, 128, 2819-2819.	1.4	4
118	MRX2843, a Novel Dual MerTK-FLT3 Inhibitor with Activity Against Resistance-Conferring FLT3 Mutations in Acute Myeloid Leukemia. Blood, 2014, 124, 3757-3757.	1.4	3
119	Therapeutic Targeting of Mertk and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia. Blood, 2021, 138, 1184-1184.	1.4	3
120	Discovery of Potent Peptidomimetic Antagonists for Heterochromatin Protein 1 Family Proteins. ACS Omega, 2022, 7, 716-732.	3.5	3
121	Drug discovery in academic institutions. Hematology American Society of Hematology Education Program, 2013, 2013, 300-305.	2.5	2
122	Mer Receptor Tyrosine Kinase. Annual Reports in Medicinal Chemistry, 2014, 49, 301-314.	0.9	2
123	A High-Throughput Screening-Compatible Strategy for the Identification of Inositol Pyrophosphate Kinase Inhibitors. PLoS ONE, 2016, 11, e0164378.	2.5	2
124	Novel Therapeutics Targeting Epigenetics: New Molecules, New Methods. ACS Medicinal Chemistry Letters, 2016, 7, 123-123.	2.8	2
125	MerTK activity is not necessary for the proliferation of glioblastoma stem cells. Biochemical Pharmacology, 2021, 186, 114437.	4.4	2
126	Mer Receptor Tyrosine Kinase Is A Potential Therapeutic Target in Acute Myeloid Leukemia. Blood, 2012, 120, 1317-1317.	1.4	2

#	Article	IF	Citations
127	Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Inhibit Platelet Aggregation In Vitro and Protect Mice From Arterial and Venous Thrombosis In Vivo. Blood, 2013, 122, 2296-2296.	1.4	1
128	MerTK Receptor Tyrosine Kinase Inhibition As a Potential Strategy to Augment Immune-Mediated Clearance of Acute Myeloid Leukemia. Blood, 2016, 128, 4044-4044.	1.4	1
129	Mertk Inhibition Promotes Anti-Leukemia Immunity By Reversing T Cell Suppression Via the PD-1 Axis. Blood, 2018, 132, 4019-4019.	1.4	1
130	Evaluation of UNC569, a Novel Small Molecule Mer Inhibitor for the Treatment of ALL in Vitro and in Vivo.. Blood, 2012, 120, 2607-2607.	1.4	0
131	A Small Molecule Inhibitor of the Gas6/Mer Pathway Inhibits Platelet Activation and Thrombosis with Equal Efficacy to, but Greater Potency Than, iMer, the Novel MerTK Splice Variant. Blood, 2012, 120, 3303-3303.	1.4	0
132	Mer Receptor Tyrosine Kinase Is a Novel Therapeutic Target In Multiple Myeloma. Blood, 2013, 122, 1957-1957.	1.4	0
133	Novel Small Molecule Inhibitors Of The Gas6/TAM Signaling Pathway Mediate Synergistic Inhibition Of Platelet Aggregation In Combination With ADP/P2Y Antagonists. Blood, 2013, 122, 3507-3507.	1.4	0
134	UNC1666, a Dual Mer and Flt-3 Tyrosine Kinase Small Molecule Inhibitor In Acute Myeloid Leukemia. Blood, 2013, 122, 3849-3849.	1.4	0
135	Development Of a Novel Small Molecule Inhibitor Of The Mer Tyrosine Kinase For Treatment Of Acute Lymphoblastic Leukemia. Blood, 2013, 122, 2666-2666.	1.4	0
136	UNC2025, a Small Molecule MerTK and Flt3 Tyrosine Kinase Inhibitor, Decreases Disease Burden, Prolongs Survival, and Promotes Sensitivity to Chemotherapy in Xenograft Models of Acute Leukemia. Blood, 2014, 124, 998-998.	1.4	0
137	Abstract 3339: MRX-2843, a dual MERTK and FLT3 inhibitor, mediates synergistic anti-leukemia activity in combination with BCL-2 inhibitors in acute myeloid leukemia and early T-cell precursor acute lymphoblastic leukemia. Cancer Research, 2022, 82, 3339-3339.	0.9	0